Adenosine Deaminase Deficiency: Understanding the Biology, Symptoms, and Modern Treatments

Adenosine deaminase deficiency (ADA) is a rare genetic disorder that profoundly disrupts immune development by impairing purine metabolism, leading to the toxic accumulation of adenosine and deoxyadenosine. This metabolic imbalance results in severe combined immunodeficiency (ADA-SCID), typically presenting in early infancy with recurrent infections, failure to thrive, and systemic complications such as skeletal abnormalities, neurodevelopmental delays, and pulmonary-alveolar proteinosis. Early diagnosis—supported by newborn screening, enzyme assays, and genetic testing—is essential for preventing irreversible organ damage. Treatment options have expanded significantly, ranging from enzyme replacement therapy for immediate metabolic correction to curative approaches such as hematopoietic stem cell transplantation and autologous gene therapy. Emerging advances in gene editing and global screening initiatives continue to reshape the therapeutic landscape. This review highlights the biological foundations, clinical manifestations, diagnostic pathways, and evolving treatment strategies for ADA deficiency, emphasizing the role of modern molecular medicine in improving patient outcomes.

Introduction: What Is Adenosine Deaminase (ADA) Deficiency?

Adenosine deaminase (ADA) deficiency is a rare but profoundly serious inherited disorder that disrupts one of the body’s most essential biochemical pathways: purine metabolism. ADA is an enzyme responsible for breaking down adenosine and deoxyadenosine, two compounds that—if allowed to accumulate—become toxic to developing immune cells. When ADA function is absent or severely impaired due to mutations in the ADA gene, these metabolites accumulate to dangerous levels. The result is widespread damage to lymphocytes, the white blood cells that coordinate immune responses. This immunological collapse forms the basis of adenosine deaminase–deficient severe combined immunodeficiency (ADA-SCID), one of the most severe forms of primary immunodeficiency.

ADA deficiency typically presents in early infancy, often within the first few months of life. Affected infants may struggle with persistent infections, chronic respiratory issues, failure to thrive, and other complications that reflect the profound loss of immune protection. While the immune system is the most visibly affected, ADA deficiency is increasingly recognized as a multisystem disorder. Toxic metabolite buildup also disrupts bone development, neurological function, and lung physiology—leading to skeletal abnormalities, neurodevelopmental delays, and pulmonary-alveolar proteinosis in some patients.

Because ADA deficiency is both rare and rapidly progressive, early recognition is critical. Newborn screening programs, where available, have dramatically improved early detection by identifying infants before severe infections occur. Diagnostic evaluation typically includes measurement of ADA enzyme activity, immunophenotyping to assess lymphocyte numbers and function, and genetic testing to confirm pathogenic variants.

Understanding ADA deficiency is essential not only for clinicians but also for families navigating diagnosis and treatment. The condition is life-threatening without prompt intervention, yet modern therapies—from enzyme replacement to hematopoietic stem cell transplantation and gene therapy—have transformed outcomes for many patients. As research advances, ADA-SCID remains a landmark condition in immunology, genetics, and the development of curative cell-based therapies.

Biological Basis: How ADA Deficiency Disrupts the Immune System

Adenosine deaminase (ADA) plays a crucial role in purine metabolism, a pathway responsible for recycling and breaking down nucleotides within cells. In individuals with ADA deficiency, the absence or severe reduction of ADA activity triggers the accumulation of adenosine and deoxyadenosine, along with their phosphorylated derivatives. These metabolites, especially deoxyadenosine triphosphate (dATP), are highly toxic to developing lymphocytes. dATP interferes with DNA synthesis and repair, ultimately causing apoptosis of T, B, and natural killer (NK) cells. This cascade of cellular dysfunction results in the profound immunosuppression characteristic of ADA-deficient severe combined immunodeficiency (ADA-SCID).

While lymphocyte depletion is the hallmark of ADA deficiency, the metabolic imbalance affects multiple organ systems. Toxic purine metabolites circulate systemically, disrupting the function of various tissues with high metabolic demands. In the skeletal system, ADA deficiency has been associated with rib and vertebral abnormalities, potentially due to impaired osteoblast development and chronic cellular stress. Neurological manifestations, including developmental delays and behavioral abnormalities, are thought to result from metabolite interference with neuronal differentiation and neurotransmitter pathways. These findings underscore that ADA deficiency is not solely an immune disorder but a multisystem metabolic disease.

Pulmonary complications are another important manifestation. Some patients develop pulmonary-alveolar proteinosis (PAP), a condition where surfactant accumulates abnormally in the alveoli. The mechanism linking ADA deficiency to PAP is not completely understood, but impaired macrophage function and disrupted purine signaling likely play central roles. These pulmonary effects can contribute to early respiratory distress and increase susceptibility to infections.

Fig. 1 Biological Impact of ADA Deficiency: From Purine Metabolism to Multisystem Damage

The severity of ADA-SCID reflects the central role of purine metabolism in early immune development. Without functional ADA, the thymus cannot support normal T-cell maturation, leading to markedly reduced T-cell counts and dysfunctional immune responses. The systemic nature of the metabolic disturbance also explains why timely diagnosis and metabolic correction are essential to prevent irreversible organ damage.

Understanding the biological mechanisms behind ADA deficiency has been instrumental in shaping current therapeutic strategies. Enzyme replacement, stem cell transplantation, and gene therapy all aim to restore metabolic balance and reestablish normal immune development—highlighting the direct link between biochemical dysfunction and clinical intervention.

Clinical Presentation and Diagnosis

Adenosine deaminase (ADA) deficiency typically presents early in life because of its profound impact on immune development. Most affected infants show symptoms within the first few weeks to months, reflecting the rapid decline in functional lymphocytes. One of the most common clinical features is recurrent, persistent, or severe infections. These infections may involve the respiratory tract, gastrointestinal system, or generalized sepsis, and they often arise from organisms that rarely cause disease in immunocompetent infants. Failure to thrive, chronic diarrhea, and poor weight gain are also frequent early indicators, reflecting the inability of the immune system to control pathogens and maintain normal physiological function.

In addition to classical signs of severe combined immunodeficiency (SCID), ADA deficiency presents with several non-immunologic manifestations. Pulmonary complications such as pulmonary-alveolar proteinosis (PAP) may cause respiratory distress or hypoxemia. Neurological symptoms—including developmental delays, hypotonia, or behavioral abnormalities—can occur due to the toxic accumulation of purine metabolites affecting neural tissues. Skeletal abnormalities, including rib cage and vertebral anomalies, have been reported in some patients, highlighting the systemic effect of ADA dysfunction.

Early diagnosis is essential for improving outcomes. Newborn screening for SCID, now implemented in many regions, has significantly improved early detection by measuring T-cell receptor excision circles (TRECs), a marker of newly formed T cells. Infants with ADA deficiency typically show profoundly low TREC levels, prompting further evaluation. Laboratory assessment includes measurement of ADA enzyme activity, which is markedly reduced or absent in ADA-SCID. Immunophenotyping reveals severe lymphopenia affecting T, B, and natural killer (NK) cells, while genetic testing confirms pathogenic variants in the ADA gene.

Additional metabolic assessments may detect elevated levels of adenosine, deoxyadenosine, and their toxic derivatives, providing further diagnostic confirmation. Radiological evaluation may be used when skeletal or pulmonary abnormalities are suspected. Together, these diagnostic tools enable clinicians to distinguish ADA deficiency from other causes of SCID and guide timely initiation of therapy.

Recognizing the broad clinical spectrum and systemic nature of ADA deficiency is crucial for clinicians. Early identification not only prevents life-threatening infections but also increases the likelihood of successful immune restoration through enzyme replacement, stem cell transplantation, or gene therapy.

Current Treatment Options: From Enzyme Replacement to Gene Therapy

The therapeutic landscape for adenosine deaminase (ADA) deficiency has advanced significantly over the past several decades, offering multiple pathways to restore immune function and improve survival. Three main treatment options exist today: enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), and gene therapy. Each approach addresses the underlying metabolic and immunological defects of ADA deficiency with varying degrees of durability and clinical benefit.

Enzyme Replacement Therapy (ERT) is often the first treatment initiated, particularly when rapid metabolic correction is needed. Using pegylated bovine ADA (PEG-ADA), ERT breaks down the toxic purine metabolites that accumulate in untreated patients. This metabolic relief allows partial recovery of lymphocyte function and can stabilize or improve clinical symptoms. However, ERT is not curative. Immune reconstitution remains incomplete, and the infused enzyme must be administered weekly for life. Additionally, the patient’s reconstituted immune system may eventually produce antibodies against the therapeutic enzyme, reducing its effectiveness over time. For these reasons, ERT is frequently used as a bridge to more definitive therapies.

Hematopoietic Stem Cell Transplantation (HSCT) has long been considered the treatment of choice, especially when a matched sibling donor is available. By replacing the patient’s defective hematopoietic stem cells with healthy ones, HSCT can restore lifelong ADA activity and reestablish a functional immune system. Outcomes are excellent when donors are well matched, with high rates of sustained immune recovery. Unrelated donor transplants are possible but carry a higher risk of graft-versus-host disease and transplantation-related complications. Despite these risks, HSCT remains a vital curative option.

Gene Therapy represents one of the most transformative advancements in ADA deficiency treatment. Using autologous hematopoietic stem cells corrected with a functional ADA gene, gene therapy avoids the immunological risks associated with donor-derived HSCT. Clinical studies have demonstrated durable immune reconstitution, reduced infections, and discontinuation of ERT in many patients. Importantly, gene therapy offers a personalized, potentially curative solution for individuals without suitable stem cell donors. As techniques continue to evolve—particularly with lentiviral vectors—the long-term safety and efficacy of gene therapy further solidify its role in modern ADA-SCID management.

Together, these therapeutic options highlight the progress made in transforming ADA deficiency from a fatal newborn condition into a treatable, and often curable, disorder.

Future Directions and Key Takeaways

The future of adenosine deaminase (ADA) deficiency management is shaped by rapid advancements in molecular medicine, gene editing, and personalized therapeutics. While current treatments—enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), and gene therapy—have dramatically improved survival and quality of life, ongoing research aims to refine these approaches and develop strategies that provide safer, more durable, and more accessible cures.